Loading...
01/11 13:47
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture: strong gross margins and positive market access developments are offset by increased expenses and non-cash losses. The Q&A reveals some uncertainty, particularly regarding sales projections and treatment kit data. The company's strategic focus on trials and market expansion is promising, but lack of specific guidance tempers enthusiasm. Given these factors, the stock price is likely to remain stable in the short term.
Revenue from cell therapy products $17.2 million, up 191% year-over-year. This growth was driven by the successful launch of Ryoncil in the final quarter of the year, with $13.2 million in gross sales and $11.3 million in reported net sales after a 14.6% gross-to-net adjustment.
Net operating cash spend $50 million, very similar to the prior year. This was despite investments in costs related to the commercial team build-out and activities around product launch.
Cash on hand $162 million (AUD 247 million) as of June 30, 2025.
Cost of revenues related to product sales $1.2 million, which is 10% of net product sales, resulting in a gross margin of 90%. Additionally, $3.9 million of expenses were related to non-cash amortization of the intangible value of prior MSC asset acquisition.
Selling, general and administrative expenses $39.3 million for FY 2025, an increase of $14.3 million year-over-year. This increase was related to the commercial team build and product launch.
Revaluation of contingent consideration A loss of $14.9 million in FY 2025, due to non-cash revaluation of potential future third-party payments.
Revaluation of warrant liability A loss of $5 million in FY 2025, compared to a gain of $0.8 million in FY 2024. This was due to FDA approval of Ryoncil and the consequential share price appreciation.
Ryoncil launch: Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, was launched for pediatric steroid-refractory acute graft-versus-host disease (GvHD). It generated $13.2 million in gross sales and $11.3 million in net sales within its first quarter of availability.
Pipeline development: Two additional assets, remestemcel-L and rexlemestrocel-L, are in Phase III trials targeting inflammatory bowel disease, chronic heart failure, and chronic low back pain.
Market opportunity: Ryoncil's addressable market for pediatric and adult GvHD is $1 billion, while inflammatory bowel disease and chronic low back pain each represent over $10 billion in market opportunities.
Market expansion: Ryoncil has been adopted by 32 transplant centers in the U.S., with plans to onboard 45 centers covering 80% of pediatric bone marrow transplants. Medicaid coverage is now mandated across all states.
Revenue growth: Revenue from cell therapy products increased by 191% to $17.2 million, driven by Ryoncil's launch.
Cost management: Net operating cash spend remained stable at $50 million despite investments in commercial team build-out and product launch.
Label expansion: Plans to expand Ryoncil's label to adults with GvHD and initiate trials for inflammatory bowel disease.
Regulatory progress: Discussions with the FDA for accelerated approval of Revascor for chronic heart failure and confirmatory trials for rexlemestrocel-L in chronic low back pain are ongoing.
Regulatory Hurdles: The company faces challenges in obtaining FDA approval for label expansion of Ryoncil to adults with GvHD and for other indications like inflammatory colitis. Regulatory requirements for confirmatory trials and chemistry, manufacturing, and controls (CMC) processes are significant hurdles.
Market Competition: The company operates in highly competitive markets, including treatments for inflammatory bowel disease, chronic low back pain, and heart failure. Competing therapies, including biologics and other advanced treatments, could limit market share.
Economic Uncertainties: The company’s financial performance is heavily reliant on the successful commercialization of Ryoncil and other pipeline products. Any economic downturns or changes in healthcare funding could adversely impact sales and operations.
Strategic Execution Risks: The company is investing heavily in clinical trials, product launches, and commercial team build-outs. Delays or failures in these areas could significantly impact financial performance and strategic objectives.
Supply Chain Disruptions: The company relies on specialized manufacturing processes for its mesenchymal stromal cell products. Any disruptions in the supply chain or manufacturing could delay product availability and impact revenue.
Financial Risks: The company reported a net operating cash spend of $50 million for the year, with significant investments in commercial activities. Sustained high expenses without proportional revenue growth could strain financial resources.
Ryoncil Label Expansion: The company plans to commence a registration trial for label expansion of Ryoncil in adults with steroid-refractory acute graft-versus-host disease (GvHD). This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN).
Inflammatory Colitis Study: A pivotal study for Ryoncil in medically-refractory inflammatory colitis is planned, focusing on early remission in patients with biologic-refractory inflammation.
Revascor Accelerated Approval: The company is preparing for an accelerated approval filing for Revascor, targeting chronic heart failure in adults with low ejection fraction. The FDA has indicated that the totality of trial results could support this pathway under the RMAT designation.
Rexlemestrocel-L for Chronic Low Back Pain: A confirmatory Phase III trial for rexlemestrocel-L in chronic low back pain is actively enrolling across multiple U.S. sites. The trial aims to confirm pain reduction at 12 months as the primary endpoint, with completion expected by the end of this year or the first quarter of next year.
The selected topic was not discussed during the call.
The earnings call presents a mixed picture: strong gross margins and positive market access developments are offset by increased expenses and non-cash losses. The Q&A reveals some uncertainty, particularly regarding sales projections and treatment kit data. The company's strategic focus on trials and market expansion is promising, but lack of specific guidance tempers enthusiasm. Given these factors, the stock price is likely to remain stable in the short term.
The earnings call indicates strong financial metrics with a reduced net operating cash spend and positive revenue expectations from RYONCIL. Despite regulatory and competitive risks, the FDA approval and positive payer feedback are promising. The absence of a shareholder return plan is a slight drawback, but the overall sentiment is positive due to the product's market potential and the company's proactive approach to launching and expanding RYONCIL.
The company's earnings call reveals mixed signals: positive developments like increased enrollment sites for trials and positive payer feedback are offset by competitive pressures and significant financial losses. The Q&A section highlights positive payer feedback and rapid enrollment plans, but unclear timelines for FDA discussions raise concerns. The lack of a shareholder return plan and financial risks such as a substantial loss after tax further moderate the outlook. Given these factors, the stock price is likely to remain stable, leading to a neutral prediction.
The earnings call summary shows mixed signals: reduced cash usage and improved loss after tax are positive, but high cash burn and regulatory risks remain. The Q&A reveals unclear timelines for REVASCOR, adding uncertainty. Lack of new partnerships or guidance adjustments further tempers optimism. Thus, the stock price reaction is likely neutral, with no strong catalysts for a significant move.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
